Previously, we showed that mutations in cartilage oligomeric matrix protein (COMP) causes pseudoachondroplasia (PSACH; COMPopathy), a well‐recognized and clinically characterized severe dwarfing condition.(2) The MT‐COMP transgenic mouse, with the common D469del mutation that recapitulates the short stature and skeletal finding of PSACH, was used to define the pathology that specifically affects growth plate chondrocytes.(3, 4, 5, 6, 7) In this study, mechanistic‐driven therapeutic approaches in the MT‐COMP mouse were used to define the mechanisms of resveratrol therapy. Here, COMP is linked to pseudoachondroplasia.